Idarubicine
C-KIT Mutation
Children's Hospital of Soochow UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the C-KIT Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine Children's Hospital of Soochow University | Phase 2 | CCC |
Avapritinib Children's Hospital of Soochow University | Phase 2 | CCC |
Decitabine Children's Hospital of Soochow University | Phase 2 | CCC |
Cytosin-Arabinosid Children's Hospital of Soochow University | Phase 2 | CCC |
FILGRASTIM Children's Hospital of Soochow University | Phase 2 | CCC |
Dasatinib Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →